Claims

1. The use of an activin-ActRII antagonist in the manufacture of a medicament for treating or preventing anemia in a human patient in need thereof, wherein said antagonist is selected from:

an antibody that binds to activin A and disrupts ActRIIa binding,
an antibody that binds to activin B and disrupts ActRIIb binding,
an anti-ActRIIa antibody,
an anti-ActRIIb antibody,
follistatin, and
inhibin.

2. The use according to claim 1, wherein the antagonist is an antibody that binds to activin and disrupts ActRIIa binding.

3. The use according to claim 1, wherein the antagonist is an antibody that binds to activin and disrupts ActRIIb binding.

4. The use according to claim 1, wherein the antagonist is an anti-ActRIIa antibody.

5. The use according to claim 1, wherein the antagonist is an anti-ActRIIb antibody.

6. The use according to claim 1, wherein the antagonist is follistatin.

7. The use according to claim 6, wherein the antagonist is follistatin-288.

8. The use according to claim 6, wherein the antagonist is follistatin-315.

9. The use according to claim 1, wherein the antagonist is inhibin.

10. The use according to any preceding claim, wherein the anemia is associated with multiple myeloma, chronic renal disease or failure, acute renal disease or failure, chemotherapeutic treatment of the patient, a myelodysplastic syndrome or a thalassemia.